<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081404</url>
  </required_header>
  <id_info>
    <org_study_id>3155105</org_study_id>
    <nct_id>NCT02081404</nct_id>
  </id_info>
  <brief_title>Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study</brief_title>
  <official_title>Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwest Biomedical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kansas City Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Midwest Biomedical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroesophageal reflux disease (GERD), a common chronic disorder in the veteran population,
      is associated with drug costs exceeding $ 10 billion/year. Only 30-40% of patients with
      reflux symptoms have erosive esophagitis. The vast majority suffers from non erosive reflux
      disease (NERD), a condition in which standard endoscopy fails to identify any mucosal breaks
      and is unable to confirm the diagnosis. Unfortunately, a gold standard for the diagnosis of
      NERD does not exist. Narrow band imaging (NBI) utilizes spectral narrow band filters
      (incorporated into standard endoscopes) and helps to see abnormal areas not identified during
      standard endoscopy. Preliminary results have shown that NBI endoscopy may represent a
      significant improvement over standard endoscopy for the diagnosis of NERD. The purpose of
      this study is to accurately diagnosis non acid reflux disease by using a blue light (also
      known as NBI)upper endoscopy technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal reflux disease (GERD), a common chronic disorder in the veteran population,
      is associated with drug costs exceeding $ 10 billion/year. Only 30-40% of patients with
      reflux symptoms have erosive esophagitis. The vast majority suffers from NERD; a condition in
      which standard endoscopy fails to identify any mucosal breaks and is unable to confirm the
      diagnosis. Unfortunately, a gold standard for the diagnosis of NERD does not exist. 24-hour
      esophageal pH monitoring and histologic esophageal mucosal changes in NERD patients have
      limited accuracy to be routinely used in clinical practice.

      Narrow band imaging (NBI) utilizes spectral narrow band filters (incorporated into standard
      endoscopes) and enables imaging of features such as intrapapillary capillary loops (IPCLs);
      features not identified during standard endoscopy. Preliminary results have shown that NBI
      endoscopy may represent a significant improvement over standard endoscopy for the diagnosis
      of NERD. Our hypothesis is that NBI identifies changes in the distal esophagus that are
      specific for diagnosing patients with NERD. Specific Aim #1: To compare NBI features in the
      distal esophagus in patients with NERD (cases) and controls. Specific Aim #2: To determine
      whether the NBI features in NERD patients resolve after PPI therapy. Specific Aim #3: To
      correlate NBI findings with esophageal histology. Specific Aim #4: To assess the intra- and
      interobserver agreement for recognition of the proposed criteria for diagnosing NERD. Cases
      will be defined as patients with reflux symptoms (assessed by two validated questionnaires)
      with absent macroscopic erosions and abnormal esophageal pH results (NERD group). Control
      subjects will include patients with no reflux symptoms, absent macroscopic erosions and a
      normal esophageal pH result. To identify NBI findings as predictors of response, response to
      therapy in cases randomized to the PPI arm will be assessed using a validated GERD
      questionnaire and correlated with IPCL number and presence of microerosion. In addition, NBI
      findings in patients with reflux symptoms, no macroscopic erosions and normal esophageal pH
      result will also be compared with controls. Two biopsies will be obtained from the distal
      esophagus along with digital images and videorecordings.

      Statistical analysis will be done as follows: Aim 1 - chi-square and t-test; with logistic
      regression and calculation of odds ratios, Aim 2- McNemar's test and kappa statistic, Aim 3-
      Spearman's correlation coefficient and Aim 4- intraclass correlation coefficient. Potential
      impact on Health Care: GERD is common among patients and by obviating the need for additional
      investigations and reducing unnecessary drug costs, NBI endoscopy could have a considerable
      positive impact on patients with NERD.

      VA Project
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NBI endoscopy identifies changes in the distal esophagus that are specific for diagnosing patients with Non-Esophageal Reflux Disease.</measure>
    <time_frame>10 weeks</time_frame>
    <description>Proportion of patients with NBI abnormalities in the NERD group vs. controls.
Proportion of patients with resolution of NBI abnormalities after PPI therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Non-erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>proton pump inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>standard dose of proton pump inhibitor by mouth once a day for 30 days</description>
    <arm_group_label>Esomeprazole</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  Capable of giving informed consents.

          -  Cases of NERD will be recruited on the basis of presence of heartburn and/or
             regurgitation using two validated GERD questionnaires in conjunction with an abnormal
             esophageal pH result and absence of erosions at standard endoscopy.

          -  Control subjects will include patients referred for an upper endoscopy for evaluation
             of non-reflux symptoms such as iron deficiency anemia, heme positive stools, screening
             of esophageal varices amongst others. A negative esophageal pH result and absence of
             erosions will be inclusion criteria for these patients.

        Exclusion Criteria:

          -  Presence of macroscopic erosive esophagitis

          -  Pregnancy/lactation

          -  Chronic anticoagulation

          -  Patients with significant medical comorbidities (oxygen dependent chronic obstructive
             pulmonary disease, NYHA class III or IV congestive heart failure, recent diagnosis of
             cancer with a life-expectancy &lt; 5 years)

          -  History of Barrett's esophagus

          -  Presence of columnar lined distal esophagus on endoscopy with intestinal metaplasia

          -  Presence of cancer or mass lesion in the esophagus or stomach

          -  Esophageal strictures

          -  Peptic ulcer disease and Helicobacter pylori infection

          -  Prior history of esophageal surgery

          -  Allergic to PPIs

          -  Patients on drugs known to cause pill-related esophagitis (e.g. potassium supplements)

          -  Patients with HIV or other immunocompromised conditions who may have infectious
             esophagitis

          -  Eosinophilic esophagitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prateek Sharma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Office of Research and Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April D Higbee, RN, BSN</last_name>
    <phone>816-861-4700</phone>
    <phone_ext>57456</phone_ext>
    <email>april.higbee@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Veterans Affairs Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April D. Higbee, R.N., B.S.N.</last_name>
      <phone>816-861-4700</phone>
      <phone_ext>7456</phone_ext>
      <email>april.higbee@va.gov</email>
    </contact>
    <investigator>
      <last_name>Prateek Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Medical Center</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarmed S Sami, MRCP</last_name>
      <phone>01158231039</phone>
      <email>sarmed.sami@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Krish Raghunath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sharma P, Wani S, Bansal A, Hall S, Puli S, Mathur S, Rastogi A. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007 Aug;133(2):454-64; quiz 674. Epub 2007 Jun 8.</citation>
    <PMID>17681166</PMID>
  </reference>
  <reference>
    <citation>Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005 May;54(5):710-7. Review.</citation>
    <PMID>15831922</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26. Epub 2006 Dec 4. Review.</citation>
    <PMID>17142109</PMID>
  </reference>
  <reference>
    <citation>Liu JY, Woloshin S, Laycock WS, Rothstein RI, Finlayson SR, Schwartz LM. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch Intern Med. 2004 Oct 11;164(18):2058-64.</citation>
    <PMID>15477443</PMID>
  </reference>
  <reference>
    <citation>McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996 Apr;38(4):481-6.</citation>
    <PMID>8707073</PMID>
  </reference>
  <reference>
    <citation>Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001 Jul;96(7):1998-2004.</citation>
    <PMID>11467624</PMID>
  </reference>
  <reference>
    <citation>Kulig M, Nocon M, Vieth M, Leodolter A, Jaspersen D, Labenz J, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol. 2004 Jun;57(6):580-9.</citation>
    <PMID>15246126</PMID>
  </reference>
  <reference>
    <citation>Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003 Oct 15;18(8):767-76.</citation>
    <PMID>14535869</PMID>
  </reference>
  <reference>
    <citation>Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol. 2002 Aug;97(8):1901-9. Review.</citation>
    <PMID>12190152</PMID>
  </reference>
  <reference>
    <citation>Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007 Feb;41(2):131-7. Review.</citation>
    <PMID>17245209</PMID>
  </reference>
  <reference>
    <citation>Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalväg A, Junghard O, Wiklund I. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998 Feb;10(2):119-24.</citation>
    <PMID>9581986</PMID>
  </reference>
  <reference>
    <citation>Venables TL, Newland RD, Patel AC, Hole J, Copeman MB, Turbitt ML. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol. 1997 Jul;32(7):627-32.</citation>
    <PMID>9246699</PMID>
  </reference>
  <reference>
    <citation>Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1091-8.</citation>
    <PMID>14653828</PMID>
  </reference>
  <reference>
    <citation>An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut. 1999 Apr;44 Suppl 2:S1-16.</citation>
    <PMID>10741335</PMID>
  </reference>
  <reference>
    <citation>Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004 May;53 Suppl 4:iv1-24. Review.</citation>
    <PMID>15082609</PMID>
  </reference>
  <reference>
    <citation>Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology. 1996 Jun;110(6):1982-96. Review.</citation>
    <PMID>8964428</PMID>
  </reference>
  <reference>
    <citation>Quigley EM. 24-h pH monitoring for gastroesophageal reflux disease: already standard but not yet gold? Am J Gastroenterol. 1992 Sep;87(9):1071-5.</citation>
    <PMID>1519562</PMID>
  </reference>
  <reference>
    <citation>Pandolfino JE, Lee TJ, Schreiner MA, Zhang Q, Roth MP, Kahrilas PJ. Comparison of esophageal acid exposure at 1 cm and 6 cm above the squamocolumnar junction using the Bravo pH monitoring system. Dis Esophagus. 2006;19(3):177-82.</citation>
    <PMID>16722995</PMID>
  </reference>
  <reference>
    <citation>Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol. 2003 Apr;98(4):740-9.</citation>
    <PMID>12738450</PMID>
  </reference>
  <reference>
    <citation>Hirano I, Richter JE; Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007 Mar;102(3):668-85.</citation>
    <PMID>17335450</PMID>
  </reference>
  <reference>
    <citation>Satoh K, Yamamoto H, Kawata H, Osawa H, Hanatsuka K, Kita H, Sunada K, Hirasawa T, Yoshizawa M, Ajibe H, Satoh Y, Sunada F, Sugano K. Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:105-10.</citation>
    <PMID>15943856</PMID>
  </reference>
  <reference>
    <citation>Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172-80.</citation>
    <PMID>10403727</PMID>
  </reference>
  <reference>
    <citation>Amano Y, Ishimura N, Furuta K, Okita K, Masaharu M, Azumi T, Ose T, Koshino K, Ishihara S, Adachi K, Kinoshita Y. Interobserver agreement on classifying endoscopic diagnoses of nonerosive esophagitis. Endoscopy. 2006 Oct;38(10):1032-5.</citation>
    <PMID>17058170</PMID>
  </reference>
  <reference>
    <citation>Kiesslich R, Kanzler S, Vieth M, Moehler M, Neidig J, Thanka Nadar BJ, Schilling D, Burg J, Nafe B, Neurath MF, Galle PR. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004;22(2):221-7.</citation>
    <PMID>15383765</PMID>
  </reference>
  <reference>
    <citation>Yoshikawa I, Yamasaki M, Yamasaki T, Kume K, Otsuki M. Lugol chromoendoscopy as a diagnostic tool in so-called endoscopy-negative GERD. Gastrointest Endosc. 2005 Nov;62(5):698-703; quiz 752, 754.</citation>
    <PMID>16246682</PMID>
  </reference>
  <reference>
    <citation>Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004 Apr 6;140(7):518-27.</citation>
    <PMID>15068979</PMID>
  </reference>
  <reference>
    <citation>Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2007 Jan;5(1):4-16. Epub 2006 Dec 8. Review.</citation>
    <PMID>17157563</PMID>
  </reference>
  <reference>
    <citation>Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux--damaged human esophageal epithelium. Gastroenterology. 1996 Nov;111(5):1200-5.</citation>
    <PMID>8898633</PMID>
  </reference>
  <reference>
    <citation>Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, Savarino E, Parodi A, Mansi C, Fiocca R. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005 Oct;100(10):2299-306.</citation>
    <PMID>16181384</PMID>
  </reference>
  <reference>
    <citation>Gono K, Obi T, Yamaguchi M, Ohyama N, Machida H, Sano Y, Yoshida S, Hamamoto Y, Endo T. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt. 2004 May-Jun;9(3):568-77.</citation>
    <PMID>15189095</PMID>
  </reference>
  <reference>
    <citation>Kumagai Y, Inoue H, Nagai K, Kawano T, Iwai T. Magnifying endoscopy, stereoscopic microscopy, and the microvascular architecture of superficial esophageal carcinoma. Endoscopy. 2002 May;34(5):369-75.</citation>
    <PMID>11972267</PMID>
  </reference>
  <reference>
    <citation>el-Serag HB, Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut. 1997 Nov;41(5):594-9.</citation>
    <PMID>9414963</PMID>
  </reference>
  <reference>
    <citation>Sharma P, Bansal A, Mathur S, Wani S, Cherian R, McGregor D, Higbee A, Hall S, Weston A. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc. 2006 Aug;64(2):167-75.</citation>
    <PMID>16860063</PMID>
  </reference>
  <reference>
    <citation>Abstracts of Digestive Disease Week, May 17-22, 2008 and the ASGE (American Society for Gastrointestinal Endoscopy) Postgraduate Course, May 21-22, 2008. San Diego, California, USA. Gastrointest Endosc. 2008 Apr;67(5):AB57-349.</citation>
    <PMID>18578045</PMID>
  </reference>
  <reference>
    <citation>Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56.</citation>
    <PMID>9136821</PMID>
  </reference>
  <reference>
    <citation>Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999 Jun;106(6):642-9.</citation>
    <PMID>10378622</PMID>
  </reference>
  <reference>
    <citation>Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994 Jun;69(6):539-47.</citation>
    <PMID>8189759</PMID>
  </reference>
  <reference>
    <citation>Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, Fendrick AM, Jones R, Dent J, Bytzer P. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001 Jan;96(1):52-7.</citation>
    <PMID>11197287</PMID>
  </reference>
  <reference>
    <citation>Fock KM, Teo EK, Ang TL, Tan JY, Law NM. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009 Jan;7(1):54-9. doi: 10.1016/j.cgh.2008.08.030. Epub 2008 Sep 3.</citation>
    <PMID>18852068</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Midwest Biomedical Research Foundation</investigator_affiliation>
    <investigator_full_name>PRATEEK SHARMA</investigator_full_name>
    <investigator_title>Principal Investigator,</investigator_title>
  </responsible_party>
  <keyword>Non-erosive Reflux Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participants individual participant data collected in the study will be available to other researchers upon request. Participants will be identified by participant number, age, race and gender. This information will be available at the end of the study and may be requested via email to april.higbee@va.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

